Takashi Amano

For Takashi Amano's latest contributions to The Japan Times, see below:

Mum Pepper's mood swings keep Son's robot dreams on hold

Oct 28, 2016

Mum Pepper's mood swings keep Son's robot dreams on hold

Japan’s obsession with robots isn’t just a cliche. Companies have been trying to drum up enthusiasm for them for years, with little success. Pepper, a humanoid machine carrying the hopes of SoftBank Group Corp.’s billionaire founder Masayoshi Son, was supposed to change that. Promoted ...

Japanese billionaire who can do no wrong sets sights on VR

Oct 26, 2016

Japanese billionaire who can do no wrong sets sights on VR

Naruatsu Baba, the 39-year old billionaire and founder of mobile game developer Colopl Inc. breaks the mold of your typical Japanese executive: he’s completely immodest about his success. “Professionally, I’ve never really made any mistakes,” Baba said in an interview, sitting next to a ...

Another Son rises in Japan seeking to improve the world

Sep 5, 2016

Another Son rises in Japan seeking to improve the world

When massive tsunami swept away entire towns in northeastern Japan five years ago, Taizo Son filled three shipping containers with emergency supplies and sent them to help the relief effort. Later, he bet almost $100 million of his own money on startups, seeking to ...

Olympus seeks deals and redemption after 2011 scandal

Jul 21, 2016

Olympus seeks deals and redemption after 2011 scandal

Five years ago, Olympus Corp. was caught up in the oddest of corporate scandals. Its then-CEO, Michael Woodford, uncovered an accounting scandal at the company that went undetected for years, besmirching the name of a once-proud Japanese maker of digital cameras and medical equipment. ...

Fujifilm's new chief aims to make drug operations profitable

Jun 3, 2016

Fujifilm's new chief aims to make drug operations profitable

Fujifilm Holdings Corp.’s new president, Kenji Sukeno, aims to make its pharmaceutical operations profitable and said the company will consider acquisitions to bolster growth in sectors where it has an existing presence. The company is targeting 20 percent operating margins in its drug operations ...